

[Gemcitabine](#)

Statut de médicament essentiel

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

Codes ATC: [L01BC05](#)

Indication

Other specified carcinomas of ovary Code ICD11: [2D23.0Y](#)

INN

Gemcitabine

Type de médicament

Chemical agent

Type de liste

Liste complémentaire

Formulations

Parenteral > General injections > IV: 200 mg in vial powder for injection ; 1 g in vial powder for injection

Historique des statuts LME

Ajouté pour la première fois en 2015 ([TRS 994](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Balises

Cancer

Wikipédia

[Gemcitabine](#)

[DrugBank](#)

[Gemcitabine](#)

Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, gemcitabine was added to the complementary list of the EML for use in treatment protocols for epithelial ovarian cancer. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for epithelial ovarian cancer is attached.